Neumora Therapeutics(NMRA) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update Announced class-leading data from diet-induced obesity (DIO) mouse model with NMRA-215, a potentially best-in- class, highly brain-penetrant, oral NLRP3 inhibitor, and expect to initiate Phase 1 study in first quarter of 2026 Advancing Phase 1 studies with two potentially best-in-class positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, with comprehensive franchise update expected by mid-202 ...